Additionally, BRCA1/2-deficient breast cancers have a higher expression of immunosuppressive molecules compared with BRCA1-WT breast cancers in WSI and TCGA cohorts, including CTLA-4, IDO1, and LAG3 [145]. This evidence concerns the gene CTLA4 and breast cancer.